This study will evaluate the percentage change in body weight from baseline and proportion of subjects achieving ≥ 5% weight loss from baseline after 52 weeks of treatment with Zovaglutide in subjects with overweight/obesity.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
755
administered subcutaneously (SC), Q4W
administered subcutaneously (SC), Q4W
administered subcutaneously (SC), Q4W
Change in body weight(%)
Time frame: baseline (week 0) to week 52
Proportion of subjects achieving ≥ 5% weight loss
Time frame: 52 weeks
Proportion of subjects achieving ≥10% weight loss
Time frame: week 52
Proportion of subjects achieving ≥15% weight loss.
Time frame: week 52
Proportion of subjects achieving ≥20% weight loss.
Time frame: week 52
Change in body weight (kg)
Time frame: Baseline (week 0) to week 52
Change in BMI (kg/m²)
Time frame: Baseline (week 0) to week 52
Change in waist circumference (cm)
Time frame: Baseline (week 0) to week 52
Change in hip circumference (cm)
Time frame: Baseline (week 0) to week 52
Number of Treatment Emergent Adverse Events (TEAEs)
Time frame: Baseline (week 0) to week 56
Number of Serious Adverse Events (SAEs)
Time frame: Baseline (week 0) to week 56
Positive rate of anti-drug antibodies (ADA).
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Xuancheng People's Hospital
Xuancheng, Anhui, China
Beijing Friendship Hospital, Capital Medical University
Beijing, Beijiing, China
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China
Gansu Provincial Hospital
Lanzhou, Gansu, China
Guangzhou Red Cross Hospital
Guangzhou, Guangdong, China
Huizhou Central People's Hospital
Huizhou, Guangdong, China
The Second Affiliated Hospotal of Guangxi Medical University
Nanning, Guangxi, China
Handan First Hospital
Handan, Hebei, China
Hebei Petro China Cental Hospital
Langfang, Hebei, China
First Hospital of Qinhuangdao
Qinhuangdao, Hebei, China
...and 35 more locations
Time frame: Baseline (week 0) to week 56
Positive rate of neutralizing antibodies (Nab)
Time frame: Baseline (week 0) to week 56